Weitz Investment Management Inc. Takes $57.76 Million Position in Thermo Fisher Scientific Inc. $TMO

Weitz Investment Management Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 115,200 shares of the medical research company’s stock, valued at approximately $57,757,000. Thermo Fisher Scientific comprises about 4.0% of Weitz Investment Management Inc.’s investment portfolio, making the stock its 9th largest position.

Several other large investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $61,080,000. Quantbot Technologies LP acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $541,000. W1M Asset Management Ltd bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $408,009,000. Varma Mutual Pension Insurance Co acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $31,193,000. Finally, George Kaiser Family Foundation bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $409,000. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 63,493 shares of company stock valued at $37,657,681. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE TMO opened at $629.02 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The firm has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company’s 50 day simple moving average is $542.53 and its 200 day simple moving average is $509.70.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.